Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1

Trial Profile

A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs E-2086 (Primary)
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Sponsors Eisai Inc

Most Recent Events

  • 08 Sep 2025 According to the Eisai Co Ltd Media Release, There were a total of 21 patients in the clinical trial (21 patients received the study medication, 19 patients completed the trial).
  • 08 Sep 2025 Results published in the Media Release
  • 03 Sep 2025 According to the Eisai Co Ltd Media Release, data from this study will be presented at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top